Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
SPYG vs XBI: how they differ
SPYG and XBI hold 1% of their weight in the same names, and XBI returned more over the year.
State Street(R) SPDR(R) Portfolio S&P 500(R) Growth ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, SPYG and XBI hold 1% of their money in the same securities at the same weight.
| Holding | SPYG | XBI |
|---|---|---|
| AbbVie Inc | 0.58% | 1.04% |
| Amgen Inc | 0.38% | 1.00% |
| Gilead Sciences Inc | 0.24% | 0.97% |
| Incyte Corp | 0.05% | 1.00% |
| Only in SPYG | Only in XBI |
|---|---|
| NVIDIA Corp 13.66% | Apogee Therapeutics Inc 1.49% |
| Microsoft Corp 7.81% | Moderna Inc 1.41% |
| Apple Inc 5.99% | Twist Bioscience Corp 1.41% |
| Alphabet Inc 5.91% | Oruka Therapeutics Inc 1.38% |
| Broadcom Inc 5.04% | Kymera Therapeutics Inc 1.36% |
| Alphabet Inc 4.71% | Viking Therapeutics Inc 1.31% |
| Micron Technology Inc 3.67% | Praxis Precision Medicines Inc 1.29% |
| Meta Platforms Inc 3.49% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| SPYG State Street(R) SPDR(R) Portfolio S&P 500(R) Growth ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | State Street | State Street |
| What it is | SPDR Portfolio S&P 500 Growth | SPDR S&P Biotech |
| Total return, 1 year | +17.9% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +0.4 pts | +46.5 pts |
| Expense ratio | 0.04% | 0.35% |
| Already in the S&P 500 | 100.0% | 8.5% |
| Holdings | 147 | 150 |
SPYG in plain words
SPYG is an index equity fund tracking the SPDR Portfolio S&P 500 Growth. Over the year to Sep 11, 2026 it returned +17.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.04% a year. By its holdings filed for Jun 30, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 147 positions, with the top ten at 56.4%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, SPYG or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, SPYG returned +17.9% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, SPYG or XBI?
- SPYG charges 0.04% a year and XBI charges 0.35%, so SPYG is cheaper. Fees come from each fund's prospectus.
- How much do SPYG and XBI overlap with the S&P 500?
- By their latest filed holdings, 100% of SPYG and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, SPYG against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/SPYG-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources